Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Nab-Paclitaxel drug combo reduces risk of  breast cancer recurrence

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

Large doses of traditional chemotherapy drug spur immune system attack on cancer cells

Large doses of traditional chemotherapy drug spur immune system attack on cancer cells

Scientists develop new test to examine a drug's embryotoxicity in cell cultures

Scientists develop new test to examine a drug's embryotoxicity in cell cultures

Deadly inherited blood disorders cured with bone marrow transplant

Deadly inherited blood disorders cured with bone marrow transplant

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

Study shows new approach to improve survival rates for patients with stage IV Wilms tumors

Study shows new approach to improve survival rates for patients with stage IV Wilms tumors

Ludwig scientists develop and test individualized ovarian cancer vaccine

Ludwig scientists develop and test individualized ovarian cancer vaccine

Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients

Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients

Antibiotic use may affect efficacy of cancer immunotherapies

Antibiotic use may affect efficacy of cancer immunotherapies

Stem cell transplant can effectively treat patients with rare autoimmune disease, study shows

Stem cell transplant can effectively treat patients with rare autoimmune disease, study shows

Stem cell transplant improves survival among scleroderma patients

Stem cell transplant improves survival among scleroderma patients

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers